Program
Tenofovir
Also written as “Tenofovir disoproxil fumarate”, “Tenofovir DF” and “tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · HIV Infections · Hepatitis B · Acquired Immunodeficiency Syndrome · Hepatitis C, led by 12 companies.
Drug pageTenofovir: every studyMany companies study it; this page follows only the 53 they lead. All 291 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 291 open or running | phase 4since Mar 23, 2005 | Nov 2, 1999 | none ahead |
| GlaxoSmithKlineits history only | 90 open or running | phase 4since May 31, 2002 | May 31, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 30 open or running | phase 3since Mar 16, 2010 | Aug 19, 2009 | none ahead |
| Laboratorio Elea Phoenixits history only | 20 open or running | phase 4since Oct 10, 2017 | Oct 19, 2015 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Dec 7, 2006 | Dec 7, 2006 | none ahead |
| Samjin Pharmaceuticalits history only | 20 open or running | phase 4since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| Boryung Pharmaceuticalits history only | 10 open or running | phase 1since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 4since Mar 27, 2018 | Mar 27, 2018 | none ahead |
| Dong-A STits history only | 10 open or running | phase 1since Sep 22, 2015 | Sep 22, 2015 | none ahead |
| New Discoveryits history only | 10 open or running | phase 4since Mar 18, 2018 | Mar 18, 2018 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Apr 25, 2022 | Apr 25, 2022 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 4since Dec 15, 2020 | Dec 15, 2020 | none ahead |
Also a collaborator on its studies: C&R Research, Almedis and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Nov 2, 1999.
- May 10, 2006Phase 4 study in HIV InfectionsNCT00324688 · 60 enrolled · Germany
- Jul 13, 2006Phase 3 study in HIV InfectionsNCT00352053 · 87 enrolled · Brazil, Panama
- Aug 16, 2006Phase 4 study in HIV InfectionsNCT00365612 · 300 enrolled · United States, Puerto Rico
- Jan 3, 2007Phase 3 study in HIV InfectionsNCT00528957 · 97 enrolled · United States, Panama, United Kingdom
- Feb 4, 2008Phase 4 study in HIV InfectionsNCT00615745 · 115 enrolled · United Kingdom
- Mar 20, 20082 phase 4 studies in HIV InfectionsNCT00643968, NCT00648817
- Mar 27, 2008Phase 2 study in LipodystrophyNCT00647946 · 100 enrolled · United Kingdom
- Aug 13, 2008Phase 4 study in Hepatitis B, ChronicNCT00736190 · 90 enrolled · United States
- Aug 13, 20082 phase 3 studies in Hepatitis BNCT00734162, NCT00737568
- Nov 4, 2010Phase 2 study in Hepatitis BNCT01334567 · 30 enrolled · Taiwan
- Jan 13, 2011Phase 4 study in Hepatitis B, ChronicNCT01277601 · 751 enrolled · United States, Australia, Canada and more
- Jul 25, 2012Phase 3 study in Hepatitis B, ChronicNCT01651403 · 90 enrolled · United States, India, Romania and more
- Aug 21, 2012Phase 1 study in Hepatitis B, ChronicNCT01671787 · 51 enrolled · United States, Australia, Canada and more
- Jun 17, 2015Phase 4 study in Hepatitis BNCT02479880 · 30 enrolled · Belgium, France, Greece and more
- Jun 9, 2016Named tenofovirINNProposed as its International Nonproprietary Name in WHO's List 115
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 Gilead Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02479880Hepatitis B · Belgium, France, Greece and more | 4 | Terminated | Feb 28, 2018 | 30 |
| NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more | 1 | Completed | Apr 2013 | 51 |
| NCT01651403Hepatitis B, Chronic · United States, India, Romania and more | 3 | Active, not recruiting | Aug 7, 2017 | 90 |
| NCT01277601Hepatitis B, Chronic · United States, Australia, Canada and more | 4 | Completed | Aug 2014 | 751 |
| NCT01334567Hepatitis B · Taiwan | 2 | Completed | Dec 2013 | 30 |
| NCT00737568Hepatitis B · United States, Austria, Bulgaria and more | 3 | Completed | Nov 2011 | 280 |
| NCT00736190Hepatitis B, Chronic · United States | 4 | Completed | Jul 2010 | 90 |
| NCT00734162Hepatitis B · United States, Bulgaria, France and more | 3 | Completed | Mar 2011 | 106 |
| NCT00648817HIV Infections · United Kingdom | 4 | Completed | Nov 2007 | 8 |
| NCT00647946Lipodystrophy · United Kingdom | 2 | Completed | Oct 2004 | 100 |
| NCT00643968HIV Infections · France | 4 | Completed | Jun 2005 | 140 |
| NCT00615745HIV Infections · United Kingdom | 4 | Completed | Nov 2010 | 115 |
| NCT00528957HIV Infections · United States, Panama, United Kingdom | 3 | Completed | Apr 6, 2009 | 97 |
| NCT00365612HIV Infections · United States, Puerto Rico | 4 | Completed | Oct 2007 | 300 |
| NCT00352053HIV Infections · Brazil, Panama | 3 | Completed | Sep 2008 | 87 |
| NCT00324688HIV Infections · Germany | 4 | Completed | 60 | |
| NCT00307489Hepatitis B, Chronic · United States, France, Germany and more | 2 | Completed | Jan 2008 | 106 |
| NCT00298363Hepatitis B, Chronic · United States, Canada, France and more | 2 | Completed | Apr 2011 | 112 |
| NCT00158821HIV Infections | 3 | Completed | Dec 2001 | 180 |
| NCT00112047HIV Infections · United States | 3 | Completed | Feb 2005 | 517 |
| NCT00106379HIV Infections · United States | 4 | Completed | 52 | |
| NCT00016588HIV Infections · United States | – | Completed | ||
| NCT00011089HIV Infections · United States | – | UNKNOWN | ||
| NCT00007436HIV Infections · United States | 3 | UNKNOWN | ||
| NCT00002453HIV Infections · United States | – | Completed | 300 | |
| NCT00002450HIV Infections · United States, Puerto Rico | 3 | Completed | 600 | |
| NCT00002415HIV Infections · United States | 2 | Completed | 175 | |
| NCT00002396HIV Infections · United States | 1 | UNKNOWN | 60 | |
| NCT00002180HIV Infections · United States | 1 | Completed |
How it is read
Names in the registry
- “Tenofovir disoproxil fumarate”, 13 entries
- “Tenofovir”, 7 entries
- “Tenofovir DF”, 6 entries
- “tenofovir”, 5 entries
- “TDF”, 4 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 29 studies
- HIV Infections, 23 studies
- Hepatitis B, 6 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Hepatitis C, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.